Reduced ocular surface disease index (OSDI) scores in patients with isotretinoin treatment
详细信息 查看全文
- 作者：Cagatay Caglar ; Engin Senel ; Emine Sabancilar…
- 关键词：Break up time ; Dry eye ; Isotretinoin ; Meibomian gland disease ; Ocular surface disease index ; Schirmer test
- 刊名：International Ophthalmology
- 出版年：2017
- 出版时间：February 2017
- 年：2017
- 卷：37
- 期：1
- 页码：197-202
- 全文大小：
- 刊物类别：Medicine
- 刊物主题：Ophthalmology;
- 出版者：Springer Netherlands
- ISSN：1573-2630
- 卷排序：37
文摘
To evaluate the changes in ocular surface and functions of tear-film in patients treated with systemic isotretinoin, to assess diagnostic performance of ocular surface disease index (OSDI) test in the dry eye conditions in association with the use of isotretinoin, and to determine the correlation between all tear-film function tests, OSDI and the dose and duration of isotretinoin administration. One hundred and twenty eyes of 60 subjects treated with oral isotretinoin were enrolled. All patients underwent ophthalmic examination at the baseline and another examination during the course of treatment. Biomicroscopic ophthalmic examination of the meibomian glands, non-anesthetized Schirmer test, and tear film break-up time (BUT) were performed. Subjective ocular complaints were scored with an OSDI questionnaire. Average Schirmer scores were not significantly changed by isotretinoin treatment. There were significant differences in the average OSDI score, the average meibomian gland disease (MGD) grade and average BUT value of both eyes during the treatment compared with baseline values (p < 0.01). There was a statistically significant inverse correlation between MGD grade and BUT value. There was no significant correlation between BUT value, OSDI score, Schirmer score, MGD grade, the total and divided dose of isotretinoin and the duration of treatment. The follow-up time was 4.01 ± 1.3 months (range 1.5–6 months). Systemic isotretinoin treatment can cause alterations in the tear film and dry eye symptoms. The OSDI test can be used as a diagnostic test for patients receiving systemic isotretinoin treatment.